Ilumya Market Share

The Business Research Company

The Business Research Company’s Ilumya Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035

LONDON, GREATER LONDON, UNITED KINGDOM, November 5, 2026 /EINPresswire.com/ -- The Ilumya market is experiencing significant attention as new treatments for moderate to severe plaque psoriasis continue to advance. With evolving therapeutic approaches and increasing patient needs, understanding the factors driving this market’s growth and the emerging trends is essential to grasp its future trajectory.

Market Size and Growth Expectations for the Ilumya Market Through 2026
Over the historical period, the Ilumya market grew due to several challenges with topical psoriasis treatments, an increasing rate of chronic plaque psoriasis cases, early approval of biologic dermatology drugs, strong adoption of biologics by dermatologists, and patient demand for long-lasting skin clearance. Looking ahead, the market’s expansion is anticipated to be driven by rising penetration of biologic therapies in dermatology, growth in systemic psoriasis treatments, broader insurance coverage for biologics, advancements in cytokine-selective therapies, and enhanced patient adherence programs. Notable trends expected to shape the market include the increased use of IL-23 inhibitors, a shift toward long-acting psoriasis therapies, growing demand for biologic dermatology treatments, improved dosing convenience, and expansion of care options for moderate to severe psoriasis.

Download a free sample of the ilumya market report:
https://thebusinessresearchcompany.com/sample_request?id=74540614&type=smp&name=Ilumya%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Nov_PR

Understanding Ilumya’s Role in Treating Psoriasis
Ilumya is a prescription drug designed to manage moderate to severe plaque psoriasis in adults who qualify for systemic therapy or ultraviolet light treatment. It is a monoclonal antibody that specifically targets interleukin-23 (IL-23), a key cytokine involved in inflammation and the excessive skin cell production seen in psoriasis. By blocking IL-23, Ilumya reduces inflammation and slows the rapid turnover of skin cells, helping to alleviate symptoms such as plaques, scaling, and redness.

Primary Factors Supporting Ilumya Market Growth
The increasing prevalence of psoriasis is a major factor driving the Ilumya market forward. Psoriasis, a chronic autoimmune disorder, causes an accelerated growth of skin cells leading to red and scaly patches. Its rising incidence is attributed to improved diagnosis and awareness, environmental influences, genetic factors, obesity, and effects from certain medications and infections. Because Ilumya targets IL-23 to reduce inflammation and control skin cell production, it effectively manages moderate to severe plaque psoriasis symptoms. For example, a May 2023 report from the National Library of Medicine predicts an increase in psoriasis incidence and disability-adjusted life years (DALYs) among people aged 30 to 39 through 2030. This growing disease burden supports the expanding demand for Ilumya.

View the full ilumya market report:
https://thebusinessresearchcompany.com/report/ilumya-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Nov_PR

Increasing Healthcare Spending as a Growth Driver in the Ilumya Market
Another key driver for the Ilumya market is the rise in healthcare expenditure. Healthcare spending encompasses costs related to medical services, treatments, hospital care, and pharmaceuticals. This increase is largely fueled by an aging global population, higher rates of chronic illnesses, and greater demand for medical care. Specifically, spending on advanced treatments for moderate to severe plaque psoriasis, including biologics like Ilumya that target IL-23, is on the rise. For instance, a report from the UK’s Office for National Statistics in May 2024 showed that total healthcare expenditure grew by 5.6% in nominal terms between 2022 and 2023, compared to just 0.9% growth the previous year. This surge in spending supports the continued expansion of the Ilumya market.

Growing Investment in Clinical Trials Boosts Ilumya Market Prospects
Funding for clinical trials is also playing a crucial role in propelling the Ilumya market forward. Such funding refers to financial resources dedicated to research that evaluates the safety, effectiveness, and potential of new medical treatments. The increasing investment in clinical trials reflects a growing urgency to develop innovative therapies addressing unmet medical needs in chronic inflammatory diseases like psoriasis. Governments and organizations are committed to advancing medical research, which benefits Ilumya by supporting extensive studies of biologic therapies for moderate to severe plaque psoriasis. These efforts aid the development of evidence-based treatment protocols and next-generation dermatological solutions. For example, data from The Association of the British Pharmaceutical Industry revealed that industry-sponsored clinical trials in the UK increased from 411 in 2022 to 426 in 2023, fostering new patient treatment options and additional healthcare revenue. This rise in clinical trial funding is thus a significant contributor to Ilumya market growth.

Regional Dynamics of the Global Ilumya Market
In 2025, North America accounted for the largest share of the Ilumya market. However, the Asia-Pacific region is expected to experience the fastest growth during the forecast period. The market report covers key areas including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, providing a broad perspective on global market trends and opportunities.

Our 2026 market reports now feature expanded strategic intelligence through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, key technology and future trend analysis, along with updated graphics and tables.

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: marketing@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company

Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X